This site uses technical cookies, Analytics cookies and third-party cookies for the operation of the site and to improve the user experience.
Terminus Group was established with a team of ambitious technologists. Our shared vision was to build a platform that bridged the gap between AI and IoT (AIoT) in anticipation of what we now know as the "intelligence economy”.
TISSIUM is a privately-owned medtech company based in Paris, France and Boston, USA that is dedicated to the development and commercialization of a unique biopolymer platform to address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction.
TISSIUM is developing a portfolio of solutions that leverage its proprietary family of fully biosynthetic, biomorphic and programmable polymers, which are the foundation of the company’s technology platform. Currently, the Company has a pipeline of seven products across three verticals, including nerve repair, hernia and cardiovascular. Each product is designed to enhance the tissue reconstruction process in a unique way. The company also develops delivery and activation devices for enhanced performance and usability of its products.
TISSIUM’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013.
Tripplo is a logistics software platform that is creating the new standard for African road-freight. The platform facilitates movement of cargo between cargo owners & transporters, and then automates & optimises operations for transporters.